John Green Biography and Net Worth

CFO of Cogent Biosciences

John joined Cogent in July 2018. He brings nearly 20 years of strategic finance and accounting experience to his position, nearly half of which has been in the Biotech industry for both public and private companies. Throughout his career in Biotech he has managed the strategic build out of numerous finance teams aligning people, processes and systems to the strategic goals of the organization. This has included transactional support, strategic plan and forecasting, cash management, SEC reporting, system implementation and operational accounting. Prior to his career in Biotech, he held various senior positions in accounting firms, including PwC and EY, where he specialized in transactions within financial institutions including private equity, private credit and security issuances. He received his Bachelors of Science in Chemistry and Biology from Acadia University and is a Chartered Professional Accountant. In his spare time, you can find him on the soccer field with his 2 daughters, or spending time in Canada with his family..

How old is John L. Green?: Mr. Green is currently 44 years old. There are 3 older executives and no younger executives at Cogent Biosciences. The oldest executive at Cogent Biosciences is Dr. John Edward Robinson Ph.D., Chief Scientific Officer, who is 49 years old. Learn More on John L. Green's age.
How do I contact John L. Green?: The corporate mailing address for Mr. Green and other Cogent Biosciences executives is 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. Cogent Biosciences can also be reached via phone at (617) 945-5576 and via email at [email protected]. Learn More on John L. Green's contact information.
Has John L. Green been buying or selling shares of Cogent Biosciences?: John L. Green has not been actively trading shares of Cogent Biosciences within the last three months. Most recently, John L. Green sold 17,813 shares of the business's stock in a transaction on Monday, April 26th. The shares were sold at an average price of $8.86, for a transaction totalling $157,823.18. Learn More on John L. Green's trading history.

John L. Green Insider Trading History at Cogent Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/26/2021	Sell	17,813	$8.86	$157,823.18

John L. Green Buying and Selling Activity at Cogent Biosciences

Cogent Biosciences Company Overview

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $7.91

$7.89

$8.30

50 Day Range

MA: $10.25

$8.15

$12.30

2 Week Range

Now: $7.91

$4.28

$12.61

Volume

77,360 shs

Average Volume

1,452,812 shs

Market Capitalization

$873.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Uncover the Top Gold Stock of the Bull Market

From Huge Alerts | Ad

Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?

Click here to see how this opportunity could transform your portfolio.